Cocrystal Pharma, Inc. (NASDAQ:COCP) Short Interest Update

Cocrystal Pharma, Inc. (NASDAQ:COCP) saw a large decline in short interest during the month of May. As of May 15th, there was short interest totaling 192,682 shares, a decline of 67.1% from the April 30th total of 586,422 shares. Based on an average trading volume of 138,014 shares, the short-interest ratio is currently 1.4 days. Approximately 1.9% of the company’s shares are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings cut shares of Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $6.00.

Hedge Funds Weigh In On Cocrystal Pharma

An institutional investor recently bought a new position in Cocrystal Pharma stock. T3 Companies LLC purchased a new stake in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 52,300 shares of the company’s stock, valued at approximately $51,000. T3 Companies LLC owned approximately 0.38% of Cocrystal Pharma as of its most recent SEC filing. 6.72% of the stock is currently owned by institutional investors.

Cocrystal Pharma Stock Performance

COCP opened at $1.12 on Monday. The company has a market cap of $15.44 million, a price-to-earnings ratio of -1.53 and a beta of 1.42. The stock has a fifty day simple moving average of $1.29 and a two-hundred day simple moving average of $1.11. Cocrystal Pharma has a 12-month low of $0.86 and a 12-month high of $2.67.

Cocrystal Pharma (NASDAQ:COCP) last released its earnings results on Friday, May 15th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The firm had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.23 million. On average, analysts predict that Cocrystal Pharma will post -0.67 EPS for the current year.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.